Annexon (NASDAQ:ANNX) Director Muneer Satter Acquires 500,000 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) Director Muneer Satter bought 500,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was purchased at an average price of $2.99 per share, for a total transaction of $1,495,000.00. Following the completion of the acquisition, the director owned 7,906,024 shares of the company’s stock, valued at approximately $23,639,011.76. This trade represents a 6.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Annexon Price Performance

Shares of Annexon stock opened at $4.06 on Thursday. The business has a 50-day moving average of $3.02 and a two-hundred day moving average of $2.56. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $5.66. The company has a market capitalization of $485.71 million, a P/E ratio of -3.15 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, equities analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Annexon

Hedge funds and other institutional investors have recently bought and sold shares of the business. Matauro LLC acquired a new stake in shares of Annexon in the second quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Annexon during the 2nd quarter worth approximately $29,000. 49 Wealth Management LLC bought a new stake in Annexon in the 2nd quarter valued at $29,000. Engineers Gate Manager LP bought a new stake in Annexon in the 2nd quarter valued at $32,000. Finally, SG Americas Securities LLC acquired a new stake in Annexon during the 3rd quarter valued at $34,000.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Annexon in a report on Friday, August 15th. Zacks Research raised Annexon from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company increased their price target on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Annexon has an average rating of “Hold” and a consensus price target of $17.33.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.